NasaPharm SRL
NasaPharm reported total assets of 606,267 € at the end of the 2025 financial year (annual accounts filed with the NBB on 09 Jul 2026).
The score of NasaPharm shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
NasaPharm's annual accounts
| 2025 | |
|---|---|
| Net result | −46,265 € |
| Equity | −21,265 € |
| Cash | 598,037 € |
| EBITDA | −46,221 € |
| Total assets | 606,267 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 09 Jul 2026
NasaPharm's financial analysis
- Solvency-3.5%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of NasaPharm
NasaPharm's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1019.084.374
- VAT number
- BE1019084374
- Peppol
- Registered · 0208:1019084374 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 23 Jan 2025
- Registered office
- 4671 Blegny
- Latest accounts
- 2025 · filed on 09 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
NasaPharm (SRL) has been based in Blegny since 2025, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 46,265 € and equity of −21,265 €; its revenue is not published. Its solvency stands at -3.5%, below the median of its sector (58.2%).
Companies similar to NasaPharm
Companies in the same business, of comparable size and area, outside its group.
- Asylia Diagnostics Research and experimental development on natural sciences and engineering Leuven · balance sheet 552,090 €
- Temple OrthoBiologics Research and experimental development on natural sciences and engineering Liège · balance sheet 692,165 €
- IR 4 Research and experimental development on natural sciences and engineering Auderghem · balance sheet 865,084 €
- Dokter Fries Claerhout Research and experimental development on natural sciences and engineering Poperinge · balance sheet 906,181 €
- CTTec Research and experimental development on natural sciences and engineering Menen · balance sheet 259,750 €
- Nyemb Research and experimental development on natural sciences and engineering Tournai · balance sheet €1.15m
- ProtonW.be Research and experimental development on natural sciences and engineering Charleroi · balance sheet €1.27m
- Huisarts Nadine Costers Research and experimental development on natural sciences and engineering Knokke-Heist · balance sheet 502,719 €
Frequently asked questions about NasaPharm
What is the revenue of NasaPharm?
NasaPharm files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of NasaPharm?
In Belgium, the VAT number is the company number prefixed with BE: BE1019084374 for NasaPharm, if the company is VAT-registered. Its company number (CBE) is 1019.084.374.
Where is the registered office of NasaPharm?
According to the CBE register, the registered office of NasaPharm is in 4671 Blegny.
What is the equity of NasaPharm?
At the close of the 2025 financial year, the equity of NasaPharm amounts to -21,265 €, a solvency of -3.5% of total assets.
Who manages NasaPharm?
The register lists 2 active mandates at NasaPharm. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of NasaPharm
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →